Boehringer Ingelheim said on Friday that health centers will be subject to its limits on 340B pricing involving contract pharmacies starting Sept. 1.

News Alert

Boehringer Ingelheim Expands its 340B Drug Pricing Restrictions

Drug manufacturer Boehringer Ingelheim (BI) said on Friday that health centers will be subject to its limits on 340B pricing involving contract pharmacies starting Sept. 1. The restrictions previously applied to hospitals only. “At this time, for all other federal grantee types,” the conditions do not apply, it said.

Under BI’s 340B policy update, the company will ship health centers’ 340B-purchased drugs to multiple contract pharmacies only if the centers provide 340B contract pharmacy claims data to BI via its vendor 340B ESP. Health centers lacking an in-house pharmacy can designate a single contract pharmacy to receive and dispense 340B-purchased BI drugs. Contract pharmacies that are wholly owned by a 340B covered entity or are under common ownership with a 340B health system may apply for an exemption, BI said.

Drug manufacturer Boehringer Ingelheim (BI) said on Friday that health centers will be subject to its limits on 340B pricing involving contract pharmacies starting Sept. 1.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report